HVC
BIS icon

Healthcare Value Capital’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Healthcare Value Capital’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,375
Closed -$1.06M – 21
2020
Q1 		$1.06M Buy
+9,375
New +$1.07M 1.78% 21
2018
Q2 		– Sell
-6,250
Closed -$1.06M – 14
2018
Q1 		$1.06M Buy
+6,250
New +$1M 4.39% 8
2017
Q3 		– Sell
-25,000
Closed -$4.85M – 16
2017
Q2 		$4.85M Buy
25,000
+21,875
+700% +$4.77M 8.72% 5
2017
Q1 		$695K Sell
3,125
-3,125
-50% -$737K 1.19% 15
2016
Q4 		$1.75M Buy
+6,250
New +$1.71M 1.87% 15
2016
Q2 		– Sell
-6,250
Closed -$2.18M – 28
2016
Q1 		$2.18M Buy
+6,250
New +$2.17M 3.2% 10
2015
Q3 		– Sell
-37,500
Closed -$8.62M – 29
2015
Q2 		$8.62M Buy
37,500
+34,375
+1,100% +$8.53M 9.05% 3
2015
Q1 		$863K Buy
+3,125
New +$956K 0.94% 21
2014
Q3 		– Sell
-5,000
Closed -$2.85M – 33
2014
Q2 		$2.85M Buy
+5,000
New +$3.44M 2.39% 13

Other funds holding BIS

WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare Value Capital's BIS Position: Q1 2019 in Review

Healthcare Value Capital sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q1 2019, closing a stake of 18,750 shares — an estimated $3.45M sold.

Healthcare Value Capital first reported a position in BIS in Q1 2014 and held it in 12 quarters. The position peaked at $3.45M in Q1 2015. 8 funds tracked by Wall St. Rank hold BIS as of Q1 2019.

  • Healthcare Value Capital reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q1 2019 after selling out during the quarter.
  • Healthcare Value Capital sold 18,750 ProShares UltraShort NASDAQ Biotechnology shares in Q1 2019, an estimated $3.45M.
  • Healthcare Value Capital first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q1 2014 and held it in 12 quarters.
  • Healthcare Value Capital's ProShares UltraShort NASDAQ Biotechnology position peaked at $3.45M in Q1 2015.
  • 8 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2019.

Based on Healthcare Value Capital's 13F filing for Q1 2019, filed 14 May 2019.